Market closedNon-fractional
Ikena Oncology/IKNA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Ikena Oncology
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.
Ticker
IKNA
Sector
Healthcare
Trading on
NASDAQ
Industry
Pharmaceuticals
Headquarters
Boston, United States
Employees
34
Website
ikenaoncology.com
Ikena Oncology Metrics
BasicAdvanced
$81M
Market cap
-
P/E ratio
-$1.57
EPS
0.34
Beta
-
Dividend rate
Price and volume
Market cap
$81M
Beta
0.34
Financial strength
Current ratio
15.849
Quick ratio
15.473
Long term debt to equity
4.057
Total debt to equity
6.273
Management effectiveness
Return on assets (TTM)
-29.04%
Return on equity (TTM)
-48.28%
Valuation
Price to revenue (TTM)
19.536
Price to book
0.52
Price to tangible book (TTM)
0.52
Price to free cash flow (TTM)
-0.957
Growth
Revenue change (TTM)
-78.08%
Earnings per share change (TTM)
-14.17%
3-year revenue growth (CAGR)
-25.86%
3-year earnings per share growth (CAGR)
-53.26%
What the Analysts think about Ikena Oncology
Analyst Ratings
Majority rating from 5 analysts.
Ikena Oncology Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
-100.00%
Net income
-$16M
-17.01%
Profit margin
0.00%
-100.00%
Ikena Oncology Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.44
-$0.40
-$0.47
-$0.33
-
Expected
-$0.47
-$0.43
-$0.43
-$0.41
-$0.35
Surprise
-7.25%
-6.98%
9.81%
-20.00%
-
Ikena Oncology News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Ikena Oncology stock?
Ikena Oncology (IKNA) has a market cap of $81M as of July 27, 2024.
What is the P/E ratio for Ikena Oncology stock?
The price to earnings (P/E) ratio for Ikena Oncology (IKNA) stock is 0 as of July 27, 2024.
Does Ikena Oncology stock pay dividends?
No, Ikena Oncology (IKNA) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Ikena Oncology dividend payment date?
Ikena Oncology (IKNA) stock does not pay dividends to its shareholders.
What is the beta indicator for Ikena Oncology?
Ikena Oncology (IKNA) has a beta rating of 0.34. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Ikena Oncology stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.